Drugs / Tilrekimig
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07792941 | Aug 2026 → Feb 2027 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT06675188 | Jan → Jul 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05411588 | Jun 2022 → May 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06977581 | May 2025 → Mar 2027 expected | asthma | Pfizer | Recruiting | No outcome recorded |
| Phase 2 | NCT05995964 | Aug 2023 → Oct 2026 expected | atopic eczema | Pfizer | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07363694 | Feb 2026 → Oct 2030 expected | chronic obstructive pulmonary disease | Pfizer | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07869043 | Sep 2026 → Jun 2029 expected | asthma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07839884 | Sep 2026 → May 2034 expected | chronic obstructive pulmonary disease | Pfizer | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07783425 | Aug 2026 → Sep 2028 expected | atopic eczema | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07772921 | Aug 2026 → Jun 2029 expected | asthma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07765888 | Aug 2026 → Mar 2028 expected | atopic eczema | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Pfizer | Results Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study pfizer.com ↗
The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥75% reduction in the Eczema Area and Severity Index) at Week 16 across all evaluated doses compared to placebo. |
| 2026-03-09 | Pfizer | Results Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis pfizer.com ↗
Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Pfizer | Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study pfizer.com ↗ |
| 2026-03-09 | Pfizer | Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis pfizer.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tilrekimig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07792941 ↗ |
| Known as | PF-07275315 | “A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma” NCT07869043 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068474 ↗ |
| Route | Intravenous | “SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07275315” NCT05411588 ↗ |
| Route | Subcutaneous | “SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07275315” NCT05411588 ↗ |